Albert Bressand
Direttore/Membro del Consiglio presso Rarecells Diagnostics SAS
Posizioni attive di Albert Bressand
Società | Posizione | Inizio | Fine |
---|---|---|---|
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Albert Bressand
Statistiche
Distribuzione geografica
Francia | 2 |
Posizioni
Director/Board Member | 1 |
Settori
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Rarecells Diagnostics SAS
Rarecells Diagnostics SAS Packaged SoftwareTechnology Services Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward. | Technology Services |
- Borsa valori
- Insiders
- Albert Bressand
- Esperienza